keytruda isnt the slam dunk everyone thinks
Company: Merck (MSD)
Tags: field, strategy, quota
BMS has GPO pull-through in half my accounts. clinically preferred doesnt matter if youre fighting the formulary payer complexity in onco has gotten worse in 12 months than the prior 3 years combined. nobody at home office is saying that out loud
12 upvotes · 5 comments